In vitro characterization and in vivo efficacy of a prostaglandin E2/poly(ortho ester) implant for bone growth promotion

[1]  R. Wittenberg,et al.  Release of prostaglandins from bone and muscle after femoral osteotomy in rats. , 1991, Acta orthopaedica Scandinavica.

[2]  C. Bünger,et al.  Early hemodynamic response to tibial osteotomy in rabbits: Influence of indomethacin and prostaglandin E2 , 1991, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[3]  J. Heller,et al.  Controlled release of 5-fluorouracil from linear poly(ortho esters) , 1990 .

[4]  W. Jee,et al.  Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. , 1990, Bone.

[5]  J. Heller.  Synthesis and Use of Poly (Ortho Esters) for the Controlled Delivery of Therapeutic Agents , 1988 .

[6]  Richard W. Baker,et al.  Controlled Release of Biologically Active Agents , 1987 .

[7]  D. Kimmel,et al.  The role of bone cells in increasing metaphyseal hard tissue in rapidly growing rats treated with prostaglandin E2. , 1987, Bone.

[8]  W. Jee,et al.  Effect of 16, 16‐dimethyl prostaglandin E2 methyl ester on weanling rat skeleton: Daily and systemic administration , 1986, The Anatomical record.

[9]  K. Himmelstein,et al.  A simultaneous transport-reaction model for controlled drug delivery from catalyzed bioerodible polymer matrices , 1985 .

[10]  D. Woodbury,et al.  The effects of prostaglandin E2 in rapidly growing rats: depressed longitudinal and radial growth and increased metaphyseal hard tissue mass. , 1985, Bone.

[11]  H. Hövels-Gürich,et al.  Nebenwirkungen am Skelettsystem bei Behandlung mit Prostaglandin E , 1984 .

[12]  K. Himmelstein,et al.  Controlled release from erod1ble poly(ortho ester) drug delivery systems , 1984 .

[13]  K. Himmelstein,et al.  Drug delivery from catalysed erodible polymeric matrices of poly(ortho ester)s. , 1984, Biomaterials.

[14]  C. Hoppel,et al.  Derivatization of carboxylic acids by reaction with 4'-bromophenacyl trifluoromethanesulfonate prior to determination by high-performance liquid chromatography. , 1984, Journal of chromatography.

[15]  T. Greibrokk,et al.  High-performance liquid chromatographic separation and ultraviolet detection of prostaglandins, oxidized by pyridinium dichromate , 1983 .

[16]  J. Brenner,et al.  Periosteal changes secondary to prostaglandin administration. , 1983, The Journal of pediatrics.

[17]  J. Brenner,et al.  Prostaglandin-induced periostitis: a complication of long-term PGE1 infusion in an infant with congenital heart disease. , 1982, Radiology.

[18]  R. Stehle.  [56] Physical chemistry, stability, and handling of prostaglandins E2, F2α, D2, and I2: A critical summary , 1982 .

[19]  K. Sone,et al.  Long-term low-dose prostaglandin E1 administration. , 1980, The Journal of pediatrics.

[20]  T. Iwaya,et al.  Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease. , 1980, The Journal of pediatrics.

[21]  S. Perera,et al.  ACID- AND BASE-CATALYZED DEHYDRATION OF PROSTAGLANDIN E2 TO PROSTAGLANDIN A2 AND GENERAL-BASE-CATALYZED ISOMERIZATION OF PROSTAGLANDIN A2 TO PROSTAGLANDIN B2 , 1979 .

[22]  A. Aguiar,et al.  Kinetics of dehydration and isomerization of prostaglandins E 1 and E 2 . , 1973, Journal of pharmaceutical sciences.